Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifing genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.
1. A method of treating an individual having multiple myeloma, comprising: administering to the individual a compound that inhibits over-expression or activity of CKS1B gene or CKS1B gene product, wherein said compound with the inhibitory effect on the CKS1B is a peptide nucleic acid (PNA) or RNA-mediated interference.